These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 1088737)

  • 21. [Effect of triacetyloleandomycin, erythromycin and spiramycin on mono-oxygenase activity].
    Micheva M; Stoĭchev Ts
    Eksp Med Morfol; 1984; 23(1):28-33. PubMed ID: 6332004
    [No Abstract]   [Full Text] [Related]  

  • 22. [Blood and tissue levels of oleandomycin in man as consequence of administration by oral route of triacetyloleandomycin].
    Liani M; Porzio R; Porzio D
    Antibiotica; 1968 Dec; 6(4):368-74. PubMed ID: 5309023
    [No Abstract]   [Full Text] [Related]  

  • 23. Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione.
    Pessayre D; Tinel M; Larrey D; Cobert B; Funck-Brentano C; Babany G
    J Pharmacol Exp Ther; 1983 Mar; 224(3):685-91. PubMed ID: 6600790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ultrastructural aspects of delta infected liver biopsies.
    Canese MG; Novara R
    Prog Clin Biol Res; 1983; 143():99-106. PubMed ID: 6669588
    [No Abstract]   [Full Text] [Related]  

  • 25. Self-induction by oleandomycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. Comparison with troleandomycin.
    Pessayre D; Descatoire V; Tinel M; Larrey D
    J Pharmacol Exp Ther; 1982 Apr; 221(1):215-21. PubMed ID: 6977641
    [No Abstract]   [Full Text] [Related]  

  • 26. Cellular and humoral immune reactions in chronic active liver disease. II. Lymphocyte subsets and viral antigens in liver biopsies of patients with acute and chronic hepatitis B.
    Eggink HF; Houthoff HJ; Huitema S; Wolters G; Poppema S; Gips CH
    Clin Exp Immunol; 1984 Apr; 56(1):121-8. PubMed ID: 6713726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism of uptake of dihydroergotamine by isolated rat hepatocytes: effect of troleandomycin.
    Dumont M; de Couët G; Le Bigot JF; Erlinger S
    J Pharmacol Exp Ther; 1985 Jul; 234(1):239-43. PubMed ID: 3874283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Delay in elimination of theophylline due to troleandomycin. No effect of josamycin (author's transl)].
    Brazier JL; Kofman J; Faucon G; Perrin-Fayolle M; Lepape A; Lanoue R
    Therapie; 1980; 35(4):545-9. PubMed ID: 6970422
    [No Abstract]   [Full Text] [Related]  

  • 29. [Viral hepatitis in drug-addicts: anatomo-clinical correlations].
    Camarri E; Corsini P; Marchettini G; Almi P; de' Santi MM; del Vecchio MT; Leoncini L; Cintorino M; Luzi P; Tosi P
    Clin Ter; 1984 Aug; 110(4):311-26. PubMed ID: 6237867
    [No Abstract]   [Full Text] [Related]  

  • 30. The general properties of troleandomycin.
    Grassi C
    Quad Antibiot; 1975 Jun; ():84-101. PubMed ID: 1088739
    [No Abstract]   [Full Text] [Related]  

  • 31. Maternal environment defines blood pressure and its response to troleandomycin in spontaneously hypertensive rats.
    Basu AK; Hagley RD; Ghosh SS; Kramer L; Nance WE; Watlington CO
    Am J Hypertens; 1995 Mar; 8(3):321-4. PubMed ID: 7794583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Studies of the hepatotoxicity of triacetyloleandomycin (TAO) in humans].
    Sasso C; Arpino E
    Minerva Med; 1969 May; 60(35):1689-94. PubMed ID: 5306225
    [No Abstract]   [Full Text] [Related]  

  • 33. Determination of the physical safety factor of potential pharmacological agents.
    Korol B; Lang WJ
    J Pharm Sci; 1965 Oct; 54(10):1555-6. PubMed ID: 5295920
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of low-dose troleandomycin on theophylline clearance: implications for therapeutic drug monitoring.
    Kamada AK; Hill MR; Brenner AM; Szefler SJ
    Pharmacotherapy; 1992; 12(2):98-102. PubMed ID: 1570234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ultramorphological alterations of club-like protrusions in hepatocytes of triacetyloleandomycin treated rats.
    Garaci E; Djaczenko W; Genazzani E
    G Batteriol Virol Immunol Microbiol; 1973; 66(7-12):171-5. PubMed ID: 4547343
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of tracetyloleandomycin on the ultrastructure of the rat liver. II. Late high dose effects.
    Garaci E; Djaczenko W; Genazzani E
    Ann Sclavo; 1973; 15(3):299-318. PubMed ID: 4544204
    [No Abstract]   [Full Text] [Related]  

  • 37. TAO and theophylline.
    Weinberger M
    Hosp Pract; 1978 Jul; 13(7):22. PubMed ID: 312756
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of triacetyloleandomycin on the ultrastructure of the rat liver. I. Low dose and early high dose effects.
    Djaczenko W; Garaci E; Genazzani E
    Ann Sclavo; 1973; 15(3):281-98. PubMed ID: 4544203
    [No Abstract]   [Full Text] [Related]  

  • 39. Ultra-structural aspects of the liver following the administration of TAO.
    Caramia FG
    Quad Antibiot; 1975 Jun; ():57-67. PubMed ID: 1088737
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.